Katetrizační ablace renálního sympatiku u nemocných s rezistentní formou arteriální hypertenze

Petr Neužil, Vivek Y. Reddy, Marcela Schejbalová, Zdeněk Stárek, Dagmar Vondráková, Jan Škoda1, Jan Petrů1, Andrea Chudicová1, František Holý

Interv Akut Kardiol. 2012;11(2):48-51  

Perspektivy a možnosti lékařské techniky

Ing. Martin Augustynek

Interv Akut Kardiol. 2012;11(2):43  

Short-term clinical and echocardiographic results of patients follow-up after TAVI

Hana Línková, Jiří Knot, Petr Toušek, Viktor Kočka

Interv Akut Kardiol. 2012;11(2):53-56  

Introduction: The aortal stenosis is the most frequent valve abnormality in adult. According to Euro Hear Survey one third of patients with significant AS were contraindicated for surgical aortic valve replacement (AVR) due to a high risk of surgery. The percutaneous aortic valve replacement (TAVI) is the alternative treatment. Currently, the patients contraindicated for AVR due to a high risk of open heart surgery are indicated for TAVI. Goal: To evaluate the clinical and echocardiographic follow-up parameters for patients after TAVI. Methods: 55 patients (including 30 women) underwent TAVI in our hospital since April 2009. In 98.2 % this...

Antithrombotic therapy after heart valve surgery

Miroslava Benešová

Interv Akut Kardiol. 2012;11(2):59-66  

Degenerative valve disease is a growing problem because of the rising amount of degenerative heart valve disease and valve replacement operations among the elderly. More than 300, 000 prosthetic heart valve replacements are performed each year worldwide and this rate is projected to increase to as many as 850,000 per year by 2050. There is a higher risk of thromboembolic events following heart valve surgery; and anticoagulation and antiplatelet therapies are necessary. The drug therapy selection is dependent on the type of surgery performed and the individual risk of the patient in any given situation. This article review assesses the benefit...

Cardiac imaging using SPECT and hybrid SPECT/CT or PET/CT

Milan Kamínek, Iva Metelková, Miroslava Budíková, Lenka Henzlová, Eva Buriánková, Radim Formánek

Interv Akut Kardiol. 2012;11(2):68-74  

Integration of CT and nuclear cardiology methods have enabled noninvasive imaging of calcified and non-calcified plaques and assessing of its hemodynamic significance. CT angiography or myocardial perfusion imaging with SPECT are independent tests recommended in patients with intermediate pre-test likelihood of coronary artery disease. CT angiography would probably be convenient in low to moderate likelihood (< 50 %), typically in younger patients, and when is normal, further tests are avoided. However, abnormal or equivocal findings have to be confirmed by SPECT. Thus, hybrid imaging is essential in many cases. Compared to CT angiography alone,...

Is implantable cardioverter-defibrillators testing necessary?

Jan Lukl

Interv Akut Kardiol. 2012;11(2):76-77  

This review contains in the first part the discussion about the various type of implantable-defibrillators testing, their advantages and disadvantages. In the second part the question is discussed, whether is the testing necessary. The advantage and disadvantages of testing are discussed. Author concludes that because there are no randomized studies, the question cannot be answered. Untill the results of randomized studies are available, author recommends limited testing, e.g. single test for defibrillation safety margin.

Extensive pericardial infiltration due to dissemination of mediastinal non-Hodgkin lymphoma

Karel Bláha, František Holm, Jiří Vondrák, David Mackerle

Interv Akut Kardiol. 2012;11(2):78-80  

Pericardial effusion created due to malignancy is now the most common cause of cardiac tamponade in developed countries. We present a case report of a patient with large pericardial effusion leading in a short time to cardiac tamponade. Despite of succesfuly performed pericardial drainage, patient died of cardiac failure with expressed syndrome of pericardial constriction. Autopsy verified extensive pericardial infiltration caused by dissemination of mediastinal non-Hodgkin lymphoma, that led to constriction of the heart by tumor masses.

Prasugrel: less known facts and duration of treatment in patients with acute coronary syndrome

Miroslav Vytiska

Interv Akut Kardiol. 2012;11(2):82-84  

Prasugrel is an antiplatelet agent, inhibiting adenosinediphosphate mediated platelet activation and aggregation. Efficacy of Prasugrel was proven in the TRITON-TIMI 38 study, and the drug is recommended in patients with acute coronary syndrome (ACS) scheduled for percutaneous coronary intervention. This review is focused on some less known facts about TRITON-TIMI 38 study and their impact on treatment strategy with Prasugrel in ACS patients.

Léčba statiny u pacientů s akutním koronárním syndromem

Za kolektiv autorů:, Jan Piťha, Tomáš Štulc, Tomáš Janota, Vasiľ Hricák

Interv Akut Kardiol. 2012;11(2):89-90  

Návštěva Patrika Periera ve FN Hradec Králové

Jan Harrer

Interv Akut Kardiol. 2012;11(2):90  

Vladimír Rozsíval šedesátiletý

prof. MUDr. Jiří Kvasnička, CSc.

Interv Akut Kardiol. 2012;11(2):88  

Komentář k článku autorů Volterrani M, Cice G, Caminiti G, et al. „Effect of Carvedilol, Ivabradine or their combination on exercise capacity in patients with Heart Failure (the CARVIVA HF trial)“. Int J Cardiol 2011; 151(2):218-224.

Filip Málek

Interv Akut Kardiol. 2012;11(2):85-86